Lupin Limited (Lupin) announced the launch of Bromfenac Ophthalmic Solution, 0.07%, after having received an approval from the United States Food and Drug Administration (U.S. FDA). Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity. Bromfenac Ophthalmic solution, 0.07% is the generic equivalent of Prolensa®?

Ophthalmic Solution,0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthal mic Solution (RLD Prolensa®?) had estimated annual sales of USD 182 million in the U.S. (IQVIA MAT November 2023).